AAPL350.72-2.06 (-0.58%) ▼|ABBV292.37-2.18 (-0.74%) ▼|ABT104.93-2.52 (-2.35%) ▼|ACN240.58-7.12 (-2.87%) ▼|ADBE235.81-10.19 (-4.14%) ▼|AMAT343.11-7.14 (-2.04%) ▼|AMD489.57-14.71 (-2.92%) ▼|AMGN456.58-5.74 (-1.24%) ▼|AMT187.82-2.92 (-1.53%) ▼|AMZN257.34-0.41 (-0.16%) ▼|AVGO338.04+4.64 (+1.39%) ▲|AXP315.54-3.51 (-1.10%) ▼|BA163.68-1.54 (-0.93%) ▼|BAC49.43-0.66 (-1.31%) ▼|BKNG153.93-3.60 (-2.29%) ▼|BLK1,183.91-14.07 (-1.17%) ▼|BMY61.07-1.86 (-2.96%) ▼|BNY149.99-1.71 (-1.12%) ▼|BRK-B589.73-3.12 (-0.53%) ▼|C119.79-1.54 (-1.27%) ▼|CAT567.33-3.16 (-0.55%) ▼|CL99.60-1.39 (-1.38%) ▼|CMCSA25.48-0.13 (-0.49%) ▼|COF186.77-6.45 (-3.34%) ▼|COP139.57-0.95 (-0.68%) ▼|COST1,112.01-1.74 (-0.16%) ▼|CRM195.10-19.74 (-9.19%) ▼|CSCO94.64+0.12 (+0.12%) ▲|CVS86.54-2.05 (-2.31%) ▼|CVX216.46-0.68 (-0.31%) ▼|DE650.88-3.11 (-0.48%) ▼|DHR227.20-2.71 (-1.18%) ▼|DIS118.68-0.02 (-0.02%) ▼|DUK130.54-0.05 (-0.04%) ▼|EMR160.23-0.42 (-0.26%) ▼|FDX321.08-6.57 (-2.01%) ▼|GD357.52-2.18 (-0.60%) ▼|GE325.54+0.36 (+0.11%) ▲|GEV768.58+5.01 (+0.66%) ▲|GILD171.02+3.44 (+2.05%) ▲|GM84.24+0.63 (+0.75%) ▲|GOOG279.14-2.12 (-0.75%) ▼|GOOGL281.98-1.74 (-0.61%) ▼|GS877.40-14.14 (-1.59%) ▼|HD339.93-7.58 (-2.18%) ▼|HON221.82+3.87 (+1.78%) ▲|IBM233.41-9.10 (-3.75%) ▼|INTC54.04-1.40 (-2.53%) ▼|INTU327.00-18.56 (-5.37%) ▼|ISRG432.60-5.15 (-1.18%) ▼|JNJ279.69-2.86 (-1.01%) ▼|JPM330.55-7.67 (-2.27%) ▼|KO99.24-0.25 (-0.25%) ▼|LIN522.47-0.99 (-0.19%) ▼|LLY1,415.99-15.68 (-1.10%) ▼|LMT590.15+4.94 (+0.84%) ▲|LOW223.15-1.79 (-0.79%) ▼|LRCX208.72-2.11 (-1.00%) ▼|MA649.67-12.04 (-1.82%) ▼|MCD277.11+2.44 (+0.89%) ▲|MDLZ67.49-0.06 (-0.08%) ▼|MDT103.14+0.26 (+0.25%) ▲|META622.83-3.58 (-0.57%) ▼|MMM181.87+0.19 (+0.10%) ▲|MO78.16-0.75 (-0.94%) ▼|MRK144.11-0.36 (-0.25%) ▼|MS183.37-2.21 (-1.19%) ▼|MSFT503.42-14.58 (-2.81%) ▼|MU701.73-17.30 (-2.41%) ▼|NEE85.07-0.27 (-0.32%) ▼|NFLX59.68-1.07 (-1.76%) ▼|NKE37.32-0.95 (-2.47%) ▼|NOW93.10-6.27 (-6.31%) ▼|NVDA153.92-2.22 (-1.42%) ▼|ORCL114.48-4.61 (-3.87%) ▼|PEP143.64-2.79 (-1.91%) ▼|PFE28.51-0.36 (-1.23%) ▼|PG172.95-0.08 (-0.04%) ▼|PLTR156.81-3.58 (-2.23%) ▼|PM196.99+0.95 (+0.48%) ▲|QCOM167.13-1.39 (-0.82%) ▼|RTX197.32+2.43 (+1.25%) ▲|SBUX108.31-0.41 (-0.38%) ▼|SCHW91.20-1.75 (-1.88%) ▼|SO93.97-0.68 (-0.71%) ▼|SPG232.09-0.69 (-0.30%) ▼|T22.54+0.18 (+0.78%) ▲|TMO690.62-0.71 (-0.10%) ▼|TMUS170.21+0.20 (+0.12%) ▲|TSLA380.51+0.77 (+0.20%) ▲|TXN294.97+0.76 (+0.26%) ▲|UBER69.29-0.70 (-1.00%) ▼|UNH396.23-15.79 (-3.83%) ▼|UNP299.89-3.82 (-1.26%) ▼|UPS110.96-0.86 (-0.77%) ▼|USB59.45-0.98 (-1.62%) ▼|V419.49-6.97 (-1.63%) ▼|VZ46.33-0.01 (-0.02%) ▼|WFC82.89-1.95 (-2.30%) ▼|WMT127.83-0.58 (-0.45%) ▼|XOM167.44+0.57 (+0.34%) ▲|AAPL350.72-2.06 (-0.58%) ▼|ABBV292.37-2.18 (-0.74%) ▼|ABT104.93-2.52 (-2.35%) ▼|ACN240.58-7.12 (-2.87%) ▼|ADBE235.81-10.19 (-4.14%) ▼|AMAT343.11-7.14 (-2.04%) ▼|AMD489.57-14.71 (-2.92%) ▼|AMGN456.58-5.74 (-1.24%) ▼|AMT187.82-2.92 (-1.53%) ▼|AMZN257.34-0.41 (-0.16%) ▼|AVGO338.04+4.64 (+1.39%) ▲|AXP315.54-3.51 (-1.10%) ▼|BA163.68-1.54 (-0.93%) ▼|BAC49.43-0.66 (-1.31%) ▼|BKNG153.93-3.60 (-2.29%) ▼|BLK1,183.91-14.07 (-1.17%) ▼|BMY61.07-1.86 (-2.96%) ▼|BNY149.99-1.71 (-1.12%) ▼|BRK-B589.73-3.12 (-0.53%) ▼|C119.79-1.54 (-1.27%) ▼|CAT567.33-3.16 (-0.55%) ▼|CL99.60-1.39 (-1.38%) ▼|CMCSA25.48-0.13 (-0.49%) ▼|COF186.77-6.45 (-3.34%) ▼|COP139.57-0.95 (-0.68%) ▼|COST1,112.01-1.74 (-0.16%) ▼|CRM195.10-19.74 (-9.19%) ▼|CSCO94.64+0.12 (+0.12%) ▲|CVS86.54-2.05 (-2.31%) ▼|CVX216.46-0.68 (-0.31%) ▼|DE650.88-3.11 (-0.48%) ▼|DHR227.20-2.71 (-1.18%) ▼|DIS118.68-0.02 (-0.02%) ▼|DUK130.54-0.05 (-0.04%) ▼|EMR160.23-0.42 (-0.26%) ▼|FDX321.08-6.57 (-2.01%) ▼|GD357.52-2.18 (-0.60%) ▼|GE325.54+0.36 (+0.11%) ▲|GEV768.58+5.01 (+0.66%) ▲|GILD171.02+3.44 (+2.05%) ▲|GM84.24+0.63 (+0.75%) ▲|GOOG279.14-2.12 (-0.75%) ▼|GOOGL281.98-1.74 (-0.61%) ▼|GS877.40-14.14 (-1.59%) ▼|HD339.93-7.58 (-2.18%) ▼|HON221.82+3.87 (+1.78%) ▲|IBM233.41-9.10 (-3.75%) ▼|INTC54.04-1.40 (-2.53%) ▼|INTU327.00-18.56 (-5.37%) ▼|ISRG432.60-5.15 (-1.18%) ▼|JNJ279.69-2.86 (-1.01%) ▼|JPM330.55-7.67 (-2.27%) ▼|KO99.24-0.25 (-0.25%) ▼|LIN522.47-0.99 (-0.19%) ▼|LLY1,415.99-15.68 (-1.10%) ▼|LMT590.15+4.94 (+0.84%) ▲|LOW223.15-1.79 (-0.79%) ▼|LRCX208.72-2.11 (-1.00%) ▼|MA649.67-12.04 (-1.82%) ▼|MCD277.11+2.44 (+0.89%) ▲|MDLZ67.49-0.06 (-0.08%) ▼|MDT103.14+0.26 (+0.25%) ▲|META622.83-3.58 (-0.57%) ▼|MMM181.87+0.19 (+0.10%) ▲|MO78.16-0.75 (-0.94%) ▼|MRK144.11-0.36 (-0.25%) ▼|MS183.37-2.21 (-1.19%) ▼|MSFT503.42-14.58 (-2.81%) ▼|MU701.73-17.30 (-2.41%) ▼|NEE85.07-0.27 (-0.32%) ▼|NFLX59.68-1.07 (-1.76%) ▼|NKE37.32-0.95 (-2.47%) ▼|NOW93.10-6.27 (-6.31%) ▼|NVDA153.92-2.22 (-1.42%) ▼|ORCL114.48-4.61 (-3.87%) ▼|PEP143.64-2.79 (-1.91%) ▼|PFE28.51-0.36 (-1.23%) ▼|PG172.95-0.08 (-0.04%) ▼|PLTR156.81-3.58 (-2.23%) ▼|PM196.99+0.95 (+0.48%) ▲|QCOM167.13-1.39 (-0.82%) ▼|RTX197.32+2.43 (+1.25%) ▲|SBUX108.31-0.41 (-0.38%) ▼|SCHW91.20-1.75 (-1.88%) ▼|SO93.97-0.68 (-0.71%) ▼|SPG232.09-0.69 (-0.30%) ▼|T22.54+0.18 (+0.78%) ▲|TMO690.62-0.71 (-0.10%) ▼|TMUS170.21+0.20 (+0.12%) ▲|TSLA380.51+0.77 (+0.20%) ▲|TXN294.97+0.76 (+0.26%) ▲|UBER69.29-0.70 (-1.00%) ▼|UNH396.23-15.79 (-3.83%) ▼|UNP299.89-3.82 (-1.26%) ▼|UPS110.96-0.86 (-0.77%) ▼|USB59.45-0.98 (-1.62%) ▼|V419.49-6.97 (-1.63%) ▼|VZ46.33-0.01 (-0.02%) ▼|WFC82.89-1.95 (-2.30%) ▼|WMT127.83-0.58 (-0.45%) ▼|XOM167.44+0.57 (+0.34%) ▲|
13.9 C
New York
Tuesday, November 17, 2026
Press ReleasesEnergyRushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio's Mol-1

RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio’s Mol-1

CAMBRIDGE, Mass., Nov. 13, 2026 /PRNewswire/ — Biointron Biological USA Inc. (“Biointron”) is pleased to have supported Molence Bio’s Mol-1 project. Mol-1 demonstrates performance comparable to the leading closed-source model IsoDDE in antibody-antigen structure prediction and is capable of designing functional nanobodies from scratch. To experimentally evaluate these AI-designed candidates, Biointron conducted developability assays using RushDATA™, its wet-lab validation service for AI-designed antibodies.

Biointron's RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio’s Mol-1

The results: 23 out of 30 AI-designed candidates met at least three of the four developability criteria, demonstrating promising developability profiles.

Wet-Lab Validation with RushDATA™

AI-designed antibodies require experimental validation to demonstrate their potential as viable drug candidates. Biointron ran the developability panel on Molence Bio’s VHH-Fc candidates, measuring properties that predict manufacturability and safety, including hydrophobicity, thermal stability, self-interaction, and non-specific binding.

Each assay was benchmarked against Biointron reference antibodies, including infliximab, bevacizumab, bococizumab, gantenerumab and trastuzumab, so the designs could be compared directly with approved and clinical-stage antibodies.

Bridging AI Design and Wet-Lab Validation

RushDATA™ is Biointron’s wet-lab validation service for AI-designed antibodies, combining a capacity of 10,000+ antibodies per day with sequence-to-data turnaround in as little as 2 days with cell-free expression or 3 days with CHO expression.

The service offers multi-point binding affinity measurements by BLI or SPR, alongside developability profiling using DSF, PSR-BVP, and AC-SINS. Results are delivered as structured, model-ready datasets with API access, allowing experimental findings to feed directly into the next round of AI-guided design.

Why This Matters for AI-Driven Antibody Discovery

AI can now generate antibody binders at scale. The next challenge is proving which designs work in the lab and behave like drugs. Mol-1 shows what happens when a strong open model meets high-quality experimental data, and Biointron is proud to provide that data.

Biointron congratulates Molence Bio on the launch of Mol-1 and looks forward to supporting the researchers who build on it.

About Biointron

Founded in 2012, Biointron is a global antibody discovery CRO trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies. Our RushDATA™ platform generates wet-lab data for AI-designed antibodies at scale, expressing 10,000+ antibodies a day and delivering binding and developability results in as little as 2 days, ready to feed your models via API. We also offer end-to-end antibody services from discovery to large-scale production. Several partner projects using our CHOK1BN cell line have entered multicenter international clinical trials successfully.

Learn more about RushDATA™: https://www.biointron.com/antibody-production/rushdata.html

About Molence Bio

Molence Bio is an AI-native biotech built on their own biomolecular foundation models. Their biologists, chemists, and AI researchers work side by side to advance these models and apply them to drug discovery: unlocking targets long considered undruggable, designing better molecules, and building a pipeline of therapies for unmet medical needs.

Access the model weights: https://github.com/molence/Mol-1

Contact

Media contact: Mia Deng

Biointron

+1 (732) 790-8340

info@biointron.com

20 University Road, Suite 500, Cambridge, MA 02138 

Founded in 2012, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. From gene sequence to purified antibodies, our production takes only 2 weeks — and with RushData, our AI antibody wet lab validation service, computational predictions become experimentally confirmed candidates at high throughput.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rushdata-enables-wet-lab-validation-of-ai-designed-antibodies-generated-by-molence-bios-mol-1-302942789.html

SOURCE Biointron

Recent News